Related Experiment Videos
Suspected carbamazepine-induced hepatotoxicity
M Morales-Diaz1, E Pinilla-Roa, I Ruiz
1Infectious Disease Service, Hospital Luis Calvo Mackenna, Santiago, Chile.
Pharmacotherapy
|February 25, 1999
Summary
Carbamazepine, an anticonvulsant, can cause severe liver injury in children. Prompt drug withdrawal and corticosteroid treatment led to recovery, highlighting the need for pediatric-specific adverse event assessments.
Area of Science:
- Pediatric Hepatology
- Clinical Pharmacology
- Adverse Drug Event Analysis
Background:
- Carbamazepine is a widely used anticonvulsant for epilepsy.
- Hepatotoxicity is a known, albeit rare, adverse effect of carbamazepine.
- Assessing causality of adverse drug events is crucial for patient safety.
Observation:
- A pediatric patient on therapeutic carbamazepine doses developed severe hepatitis and hepatic insufficiency.
- The patient's liver function improved significantly after discontinuing carbamazepine and initiating corticosteroid therapy.
Findings:
- The Roussel UCLAF causality assessment method was applied, yielding a score of 8 for this acute hepatocellular event.
- This score indicates a probable causal link between carbamazepine and the observed liver injury.
- The case highlights the potential for severe hepatic adverse events in children treated with carbamazepine.
Implications:
- The Roussel UCLAF method offers a comprehensive approach to causality assessment in drug-induced liver injury.
- Adaptation of causality assessment tools is necessary for accurate evaluation of adverse events in the pediatric population.
- This case underscores the importance of vigilant monitoring for hepatotoxicity in children receiving carbamazepine.